Literature DB >> 26588090

Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition.

Lorenza Putignani1, Federica Del Chierico, Pamela Vernocchi, Michele Cicala, Salvatore Cucchiara, Bruno Dallapiccola.   

Abstract

Gastrointestinal disorders, although clinically heterogeneous, share pathogenic mechanisms, including genetic susceptibility, impaired gut barrier function, altered microbiota, and environmental triggers (infections, social and behavioral factors, epigenetic control, and diet). Gut microbiota has been studied for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) in either children or adults, while modifiable gut microbiota features, acting as risk and premorbid factors along the childhood-adulthood transition, have not been thoroughly investigated so far. Indeed, the relationship between variations of the entire host/microbiota/environmental scenario and clinical phenotypes is still not fully understood. In this respect, tracking gut dysbiosis grading may help deciphering host phenotype-genotype associations and microbiota shifts in an integrated top-down omics-based approach within large-scale pediatric and adult case-control cohorts. Large-scale gut microbiota signatures and host inflammation patterns may be integrated with dietary habits, under genetic and epigenetic constraints, providing gut dysbiosis profiles acting as risk predictors of IBD or IBS in preclinical cases. Tracking dysbiosis supports new personalized/stratified IBD and IBS prevention programmes, generating Decision Support System tools. They include (1) high risk or flare-up recurrence -omics-based dysbiosis profiles; (2) microbial and molecular biomarkers of health and disease; (3) -omics-based pipelines for laboratory medicine diagnostics; (4) health apps for self-management of score-based dietary profiles, which can be shared with clinicians for nutritional habit and lifestyle amendment; (5) -omics profiling data warehousing and public repositories for IBD and IBS profile consultation. Dysbiosis-related indexes can represent novel laboratory and clinical medicine tools preventing or postponing the disease, finally interfering with its natural history.

Entities:  

Mesh:

Year:  2016        PMID: 26588090     DOI: 10.1097/MIB.0000000000000602

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  38 in total

Review 1.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

2.  Gut Inflammation Induced by Dextran Sulfate Sodium Exacerbates Amyloid-β Plaque Deposition in the AppNL-G-F Mouse Model of Alzheimer's Disease.

Authors:  Mona Sohrabi; Heidi L Pecoraro; Colin K Combs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 3.  Metabolomics Signatures of Aging: Recent Advances.

Authors:  Sunil S Adav; Yulan Wang
Journal:  Aging Dis       Date:  2021-04-01       Impact factor: 6.745

Review 4.  Chronic oral exposure to pesticides and their consequences on metabolic regulation: role of the microbiota.

Authors:  Flore Depeint; Hafida Khorsi-Cauet; Narimane Djekkoun; Jean-Daniel Lalau; Véronique Bach
Journal:  Eur J Nutr       Date:  2021-04-10       Impact factor: 5.614

5.  Maternal Influence and Murine Housing Confound Impact of NLRP1 Inflammasome on Microbiome Composition.

Authors:  Veronica M Ringel-Scaia; Yufeng Qin; Cassidy A Thomas; Kathleen E Huie; Dylan K McDaniel; Kristin Eden; Paul A Wade; Irving C Allen
Journal:  J Innate Immun       Date:  2019-02-13       Impact factor: 7.349

6.  An Integrated Approach to Recognize Potential Protective Effects of Culinary Herbs Against Chronic Diseases.

Authors:  Suganya Chandrababu; Dhundy Bastola
Journal:  J Healthc Inform Res       Date:  2018-11-19

7.  Antimicrobial peptide CC34 attenuates intestinal inflammation via downregulation of the NF-κB signaling pathway.

Authors:  Liqiang Dong; Huan Yang; Zhao Wang; Ning Jiang; Aizhong Zhang
Journal:  3 Biotech       Date:  2021-08-04       Impact factor: 2.893

Review 8.  Mind-Body Interventions for Pediatric Inflammatory Bowel Disease.

Authors:  Ann Ming Yeh; Anava Wren; Brenda Golianu
Journal:  Children (Basel)       Date:  2017-04-03

9.  Identification of the molecular mechanisms underlying brisket disease in Holstein heifers via microbiota and metabolome analyses.

Authors:  Kun Yao; Shuxiang Wang; Naren Gaowa; Shuai Huang; Shengli Li; Wei Shao
Journal:  AMB Express       Date:  2021-06-12       Impact factor: 3.298

Review 10.  Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health.

Authors:  Pamela Vernocchi; Federica Del Chierico; Lorenza Putignani
Journal:  Front Microbiol       Date:  2016-07-26       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.